FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL

@inproceedings{MarzoOrtega2019FRI0379LE,
  title={FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL},
  author={Helena Marzo-Ortega and Joachim Sieper and Alan J. Kivitz and Ricardo Rodriguez Blanco and Patricia M. Spittal and Karel Pavelka and Eumorphia Maria Delicha and Jacek Manitius and Hedda Richards and Susanne Rohrer},
  year={2019}
}

Similar Papers

Topics from this paper.